© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Video
VIDEO: Clopidogrel bests ticagrelor in PCI for ACS in real-world study
AT THE ESC CONGRESS 2017
Related Articles
D-dimer thresholds rule out PE in meta-analysis
August 30, 2017
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
![1]()
Apixaban outmatches rivaroxaban for VTE in study
August 30, 2017
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
![1]()
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
August 30, 2017
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
August 30, 2017
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
